OBIO Stock Analysis: Buy, Sell, or Hold?
OBIO - Orchestra BioMed Holdings, Inc. Ordinary Shares
$3.98
-0.01 (-0.25%)
▼
5d:
+6.42%
30d:
-7.44%
90d:
-0.25%
BUY
HIGH Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 11, 2026
8d
Get Alerted When OBIO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: OBIO shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
✅ BUY SIGNAL: OBIO shows strong fundamentals and good volume confirmation. Solid entry point despite fair pricing.
In-depth Analysis How we analyze
Valuation Analysis: OBIO is currently trading at $3.98, which is considered fair relative to its 30-day fair value range of $3.67 to $4.18.
Technical Outlook: Technically, OBIO is in a strong downtrend. The price is approaching resistance at $4.06. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: OBIO has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $12.17 (+220.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, OBIO is in a strong downtrend. The price is approaching resistance at $4.06. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: OBIO has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $12.17 (+220.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$3.67 -
$4.18
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
89.6%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 220.2% below Wall St target ($12.17)
Trading Range Analysis
30-Day Trading Range
$3.67 -
$4.18
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$0.52
(13.1%)
Support & Resistance Levels
Support Level
$3.56
Resistance Level
$4.06
Current Trend
Strong Downtrend
Technical data as of
Jul 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.61
Wall Street Target
$12.17
(+220.2%)
Revenue Growth (YoY)
-87.3%
Profit Margin
-167.0%
Share & Embed Analysis
Last updated: August 02, 2026 3:01 PM ET
Data refreshes hourly during market hours. Next update: 4:01 PM
Data refreshes hourly during market hours. Next update: 4:01 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OBIO showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
David P Hochman
BUY
10000 shares
2026-03-13
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 53 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 55 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$282 | 54 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$33 | 60 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$105 | 56 HOLD |
